Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls.

Scientific reports - 16 Apr 2020

Behl Supriya, Hamel Nancy, de Ladurantaye Manon, Lepage Stéphanie, Lapointe Réjean, Mes-Masson Anne-Marie, Foulkes William D

Abstract excerpt

Inherited germline pathogenic variants are responsible for ~5% of breast cancer globally. Through rapid expansion and isolation since immigration in the early 17th century, French Canadians are a relatively genetically homogenous founder population and therefore represent a unique demographic for genetic contributions to disease. To date, twenty variants in BRCA1, BRCA2, and PALB2 that predispose families to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Canada

Share to Fanconi Anemia Complementation Group N Protein

Share to Founder Effect

Share to Genotyping Techniques

Share to Mass Screening

Share to Medical History Taking

Source

Open in PubMed Open full text

Identifiers

PMID: 32300229
DOI: 10.1038/s41598-020-63100-w
PMCID: PMC7162921

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls.PMID 32300229Read ↗

[The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].Semantic proximity Read ↗

Hereditary breast cancer next-generation sequencing (NGS) panel evaluation in the south region of Brazil: a novel<i>BRCA2</i>candidate pathogenic variant is reportedSemantic proximity Read ↗

The contribution of founder mutations to early-onset breast cancer in French-Canadian women.Semantic proximity Read ↗

Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women.Semantic proximity Read ↗

The spectrum of BRCA1 and BRCA2 alleles in Latin America and the Caribbean: a clinical perspective.Semantic proximity Read ↗

Prevalence of BRCA1/BRCA2 pathogenic variation in Chinese Han population.Semantic proximity Read ↗

Genetic testing women with newly diagnosed breast cancer: What criteria are the most predictive of a positive test?Semantic proximity Read ↗

A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.Semantic proximity Read ↗

Spectrum and characteristics of germline PALB2 pathogenic variants in 1556 early-onset breast cancer patients in China.Semantic proximity Read ↗

The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and/or ovarian cancer families of French Canadian descent.Semantic proximity Read ↗

Germline TP53 mutational spectrum in French Canadians with breast cancer.Semantic proximity Read ↗

Canadian Recommendations for Germline Genetic Testing of Patients with Breast Cancer: A Call to ActionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.